The overall aim of this K24 Mid-Career Investigator Award in Patient-Oriented Research is to allow Dr. Frances Levin to continue to expand her programmatic line of clinical research and mentoring. Three objectives drive the applicant's work: 1) develops pharmacotherapies that consider the heterogeneity of substance abusers 2) provides mentorship to junior clinical investigators, and 3) contribute service to the field. Primary activities and accomplishments include promoting the recognition and treatment of adult attention- deficit hyperactivity in substance abusers, developing novel combined medication treatment strategies for cocaine and cannabis-dependent individuals, and pursuing promising medications combined with motivational and behavioral treatments for cannabis dependence. During the course of the award Dr. Levin will be PI of 3 RO1s (two are multi-site controlled trials) and PI of a T32 that targets the training of physicians. Additionally, she will continue to serve as the PI of a major R01-equivalent project investigating a combined pharmacotherapy for cannabis dependence and serve as the Director of the Education Core of a long-standing Medications Development Center. Further, she will serve as a Co-PI or Co-I on several other RO1s with both junior and mid-career colleagues that extend her areas of interest. The career development plan for this application will expand Dr. Levin's knowledge into the areas of molecular genetics and neurocognition through accessing the expertise of specialists in these areas. The mentoring plan incorporates trainees at various levels of development: 1) pre-doctoral trainees;2) post- doctoral trainees (psychiatric residents or substance abuse research fellows);and 3) junior faculty. An overarching career goal has been to train and mentor clinical investigators and advance knowledge in the substance abuse field through synergistic collaborations with other investigators, often with individuals that Dr. Levin has mentored or is currently mentoring. The research and mentoring plan has major public health significance. Substance abuse is often accompanied with additional psychiatric comorbidity and effective treatments for comorbid individuals remain elusive. Moreover, there has been minimal research evaluating pharmacotherapies for cannabis dependence, despite its substantial morbidity. Of great public concern is a dearth of adequately trained physician- investigators interested in clinical substance abuse research careers. Through Dr. Levin's activities it is hoped that the treatment of substance abusers will improve, both through her research and collaborations with colleagues, and through her training of the next generation of clinical investigators.

Public Health Relevance

The objectives of this patient-oriented K24 proposal is to gain greater knowledge of novel treatment options for substance use disorders as well as possible vulnerabilities that might place certain populations at risk for substance abuse and impede treatment efficacy. These goals address a critical public health need and will be attained through the applicant's programmatic line of patient-oriented research and her mentorship of trainees, junior faculty, and other mentees such that they obtain the necessary research skills to pursue independent clinical research careers.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-KXH-C (15))
Program Officer
Aklin, Will
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Roebke, Patrick V; Vadhan, Nehal P; Brooks, Daniel J et al. (2014) Verbal learning in marijuana users seeking treatment: a comparison between depressed and non-depressed samples. Am J Drug Alcohol Abuse 40:274-9
McClure, Erin A; Sonne, Susan C; Winhusen, Theresa et al. (2014) Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials 39:211-23
Mariani, John J; Pavlicova, Martina; Mamczur, Agnieszka K et al. (2014) Open-label pilot study of quetiapine treatment for cannabis dependence. Am J Drug Alcohol Abuse 40:280-4
Mariani, John J; Khantzian, Edward J; Levin, Frances R (2014) The self-medication hypothesis and psychostimulant treatment of cocaine dependence: an update. Am J Addict 23:189-93
Dakwar, Elias; Levin, Frances R; Olfson, Mark et al. (2014) First treatment contact for ADHD: predictors of and gender differences in treatment seeking. Psychiatr Serv 65:1465-73
Raby, Wilfrid Noel; Rubin, Eric A; Garawi, Fatima et al. (2014) A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. Am J Addict 23:68-75
van de Glind, Geurt; Konstenius, Maija; Koeter, Maarten W J et al. (2014) Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug Alcohol Depend 134:158-66
Kelly, Meredith A; Pavlicova, Martina; Glass, Andrew et al. (2014) Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR? Drug Alcohol Depend 144:42-6
Dakwar, E; Anerella, C; Hart, C L et al. (2014) Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend 136:153-7
van Emmerik-van Oortmerssen, Katelijne; van de Glind, Geurt; Koeter, Maarten W J et al. (2014) Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. Addiction 109:262-72

Showing the most recent 10 out of 21 publications